AI-generated from publicly available materials.CellCarta and Imagene AI have announced an enhanced partnership aimed at streamlining AI-driven biomarker and companion diagnostic (CDx) programs for biopharma companies, with active projects already in progress with two leading global pharmaceutical firms.
This collaboration focuses on guiding projects from initial biomarker strategy through to clinical trial execution and regulatory approval. By integrating Imagene AI’s advanced assay development and biomarker prediction technologies with CellCarta’s established infrastructure for companion diagnostics, the partnership aims to provide a comprehensive framework for the development and deployment of these critical programs.
Currently, the companies are collaborating on two specific initiatives: one involves the development of an AI-powered immunohistochemistry (IHC) companion diagnostic, while the other utilizes Imagene AI’s Lung Prediction Panel for non-small cell lung cancer (NSCLC). This Lung Prediction Panel is designed to quickly identify key NSCLC biomarkers from standard tissue samples, enhancing the efficiency of biomarker-driven clinical trials.
As the collaboration progresses, both companies emphasize the necessity of a robust validation and scaling process to effectively integrate AI capabilities into clinical development. This partnership not only leverages their individual strengths but also positions them to meet the growing demands for innovative diagnostic solutions in the life sciences sector. The implications of this collaboration could significantly advance the landscape of personalized medicine, particularly in oncology.